[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584285":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":21,"locations":27,"responsibleParty":61,"collaborators":10,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":83,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Replimune, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients who received at least 1 dose of an RPx [RP1, RP2, RP3]",null,"This is an observational study and there will be no clinical interventions.",[13],"Other: Observational study with no interventions",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"OTHER","Observational study with no interventions",[9],[20],"Observational Study",[22],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Clinical Trials at Replimune","CONTACT","1-781-222-9570","Clinicaltrials@replimune.com",[28,46],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"UC San Diego Moores Cancer Center","RECRUITING","La Jolla","California","92093-0698","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-117.2742,32.84727,{"lat":40,"lon":39},[43],{"name":44,"role":45,"phone":10,"phoneExt":10,"email":10},"Soo Park, MD","PRINCIPAL_INVESTIGATOR",{"facility":47,"status":30,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Tasman Oncology Research","Southport","Queensland","4215","Australia","AU",{"type":37,"coordinates":54},[55,56],153.39796,-27.96724,{"lat":56,"lon":55},[59],{"name":60,"role":45,"phone":10,"phoneExt":10,"email":10},"Andrew Hill, MD",{"type":62,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100584285","a-study-to-assess-the-long-term-safety-outcomes-in-patients-previously-treated-with-rp1-rp2-or-rp3-100584285",false,"NCT06887348","A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3","Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products","RPx","Inclusion Criteria:\n\nPatients are eligible for inclusion in the study only if they meet all of the following criteria:\n\n1. Patient has received at least 1 dose of an RPx product and has completed or discontinued participation in the parent study.\n2. Patient or patient's legal guardian has provided signed informed consent (or assent) as , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\nPatients are excluded from the study if the following criterion applies:\n\n1\\. Cannot comply with the requirements of the study.","ALL","18 Years",{"count":74,"type":75},50,"ESTIMATED","OBSERVATIONAL","This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose of an RPx product under the interventional parent study. Patients will be rolled over into this LTFU study after completion of the Replimune-sponsored parent study (ie, either completion of the LTFU in the parent study or withdrawal from the parent study). All patients in ongoing RPx studies will be asked to participate in this LTFU study so that the Sponsor can evaluate potential delayed risks.",[79,80,81,82],"Melanoma","Metastatic Melanoma","Advanced Solid Tumor","Hepatocellular Carcinoma",[84,85,86,87,88,82,89,90,91,92],"Advanced solid tumors","Immunotherapy","Immuno-oncology","Oncolytic virus","Oncolytic immuno-gene therapy","Cutaneous Melanoma","Anti-PD1 failed","Non-melanoma Skin Cancer","Melanoma (skin)","2026-01-09",{"date":95,"type":96},"2026-01-12","ACTUAL",{"date":98,"type":96},"2025-12-12",{"date":100,"type":75},"2035-12",{"name":5,"class":6},2]